About First Round Capital
First Round Capital operates as a venture capital firm. It focuses on seed-stage investments in the technology. The company provides financial support to startups and offers additional resources such as mentorship, hiring assistance, and customer acquisition strategies. It primarily serves the technology industry, with a particular interest in the enterprise, consumer, hardware, financial technology (fintech), and healthcare sectors. It was founded in 2004 and is based in Philadelphia, Pennsylvania.
Expert Collections containing First Round Capital
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find First Round Capital in 13 Expert Collections, including Direct-To-Consumer Brands (Non-Food).
Direct-To-Consumer Brands (Non-Food)
Startups selling their own branded products directly to consumers via online/mobile channels, rather than relying on department stores or big online marketplaces.
Hardware and software for restaurant management, bookings, staffing, mobile restaurant payments, inventory management, and more.
Store tech (In-store retail tech)
Startups aiming work with retailers to improve brick-and-mortar retail operations.
Agriculture Technology (Agtech)
Companies that are using technology to make farms more efficient
Research containing First Round Capital
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned First Round Capital in 2 CB Insights research briefs, most recently on Dec 9, 2021.
Latest First Round Capital News
Dec 6, 2023
Led by Ridgeback Capital Investments LP, with participation from First Round Capital, Y Combinator, Neo, and other existing investors. News provided by Share this article Share toX CAMBRIDGE, Mass., Feb. 3, 2021 /PRNewswire/ -- Reverie Labs , a pharmaceutical company pioneering the application of machine learning to developing next-generation small molecule kinase inhibitors, today announced the closure of its $25M Series A financing, and the addition of Wayne Holman, M.D., founder and CEO of Ridgeback Capital, to Reverie's Board of Directors. This financing brings the total capital raised by Reverie to more than $32M. Reverie will use the proceeds to advance its internal and partnered drug discovery programs towards the clinic, further develop its innovative computational discovery platform, and grow its world-class, cross-disciplinary team of scientists and engineers. While tremendous progress has been made towards the advent of cancer precision medicine, for many cancer subtypes patient outcomes are still poor. Off-target toxicities limit the dose and thus the effectiveness of many drugs, and crucially prevent these drugs from being used in combination to circumvent resistance mechanisms. Reverie's goal is to contribute exquisitely specific kinase inhibitors to humanity's armamentarium for fighting disease. Reverie believes that only with access to an arsenal of targeted therapies will clinicians have the tools they need to not just produce small survival benefits, but durable, complete responses to therapy. Reverie's lead program, which is rapidly advancing towards the clinic, is targeting a well-validated disease mechanism with highly specific and brain-penetrant kinase inhibitors. Reverie is also supplementing its pipeline through carefully chosen partnerships, including a multi-target strategic collaboration agreement with Roche and Genentech, a member of the Roche Group. "Too often in the pharmaceutical industry, data is treated as a by-product of doing drug discovery, not an intentionally generated asset for the purpose of improving one's platform. This capital will allow us to prioritize data generation and double down on the personnel and technology needed to develop our best-in-class computational kinase platform," said Ankit Gupta, Reverie's co-founder and CTO. "We are tremendously excited to be working with a deeply experienced biotech fund like Ridgeback, which has supported myriad companies in rapidly advancing compounds into clinical development," added Jonah Kallenbach, Reverie's co-founder and CEO. "Additionally, this funding will allow us to aggressively expand our extraordinary team of scientists and engineers." "The Ridgeback team has watched for several years with great enthusiasm as the growing Reverie team has transformed an idea into an organization with a special ability to combine artificial intelligence and biomedical innovation to rapidly create medicines with efficiency and precision," said Wayne Holman. "Data generation in biology and drug development has accelerated dramatically over the last two decades, and the talent and skills Jonah, Ankit, and their team possess in machine learning and AI position them well to exploit that data to design better molecules to meet severe unmet needs." About Reverie Labs Reverie Labs is a pharmaceutical company leveraging machine learning, physics-based modeling, and massive-scale computational infrastructure to engineer new medicines. Reverie's technology consists of state-of-the-art predictive tools, new methods for focused molecular generation, and a scalable cloud framework, which allows for the unhindered exploration of chemical space. Reverie's unique approach has already led to the discovery of selective, brain-penetrant kinase inhibitors for oncology targets. Reverie was founded in 2017 and is headquartered in Cambridge, MA. To learn more, please email [email protected] . SOURCE Reverie Labs
First Round Capital Investments
First Round Capital has made 964 investments. Their latest investment was in Clarity as part of their Seed VC on February 06, 2024.
First Round Capital Investments Activity
Series D - II
First Round Capital Fund History
25 Fund Histories
First Round Capital has 25 funds, including First Round Capital VI.
First Round Capital Team
5 Team Members
First Round Capital has 5 team members, including , .
Compare First Round Capital to Competitors
General Catalyst is a venture capital firm that makes early-stage and transformational investments. It back entrepreneurs who are building technology companies and businesses, and invests in seed-stage, early-stage, later-stage, and growth-stage companies operating in consumer, enterprise, fintech, crypto, health assurance, software, transportation, big data, and technology sectors. The company was founded in 2000 and is based in Cambridge, Massachusetts.
GGV Capital is a venture capital fund. It deals with software and technology, media and entertainment, and telecommunications (TMT) sector companies. It was founded in 2000 and is based in Menlo Park, California.
Index Ventures operates as a global venture capital firm. It invests in the commercial services, media, retail, and information technology sectors. It was founded in 1996 and is based in London, United Kingdom.
Redpoint Ventures operates as a venture capital firm. The company invests in startups at various stages, including seed, early, and growth phases, to create new markets and redefine existing ones. The firm's main customers are startups across various sectors of the economy. It was founded in 1999 and is based in San Francisco, California.
Coatue is a global investment manager focused on public and private companies in the technology, media, and telecommunications industries. The company was founded in 1999 and is based in New York, New York.
New Enterprise Associates (NEA) provides venture capital to help entrepreneurs and business leaders build transformational, industry-leading companies. It mainly focuses on companies in the early stages of development while a significant portion of its dollars is invested in venture growth equity opportunities. NEA also invests in foreign markets including China and India across sectors including information technology, healthcare, and energy technology. It was founded in 1977 and is based in Menlo, California.